Dr. Anthony Fauci introduces John as the invited speaker for the National Institute of Allergy and Infectious Diseases annual Kinyoun lecture in December 2016. The talk focused on the challenges of developing effective vaccines against viruses such as HIV, influenza and respiratory syncytial virus as well as the use of structural information about viral proteins and antibodies in vaccine design.

United States president Barack Obama greets John during a visit to the NIH campus in December of 2014. President Obama’s visit was to discuss the progress made and the work still needed to contain and combat the Ebola outbreak.

John Mascola

Chief Scientific Officer

Dr. John Mascola joined ModeX Therapeutics as Chief Scientific Officer in 2022. He is an accomplished physician-scientist, virologist and immunologist, and was most recently the Director of the Vaccine Research Center, NIAID, NIH where he oversaw research programs on vaccines and antibody therapeutics as well as the development of investigational products for major diseases such as HIV, Ebola, respiratory syncytial virus, chikungunya and malaria. Under his leadership, the VRC established collaborative partnerships leading to the licensure of therapeutic antibodies and vaccines for Ebola and COVID-19.

Dr. Mascola earned a medical degree from Georgetown University and completed a residency in internal medicine and fellowship in infectious diseases. From 1993 to 2000, he was a research physician at the Walter Reed Army Institute of Research where he began his studies on HIV immunology and vaccine development. He joined the Vaccine Research Center at NIAID, NIH as a founding investigator in 2000 and served as its director from 2013 to 2022. Dr. Mascola has received numerous awards and recognitions, including the outstanding service medal from the U.S. Department of Health and Human Services. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the National Academy of Medicine.